![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_130,h_50,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_500,h_200,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
Updated: Dec 15, 2022
We had a kick-off networking event with the DISRUPT team and guests that included directors from Columbia, Mount Sinai, and Einstein/Montefiore Cancer Centers, as well as City College of New York.
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial...
A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) This is a platform...
A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH...
Comments